Gene - therapy for rare diseases
搜索文档
Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder
Benzinga· 2026-01-28 02:03
The U.S. Food and Drug Administration (FDA) on Tuesday said it removed the clinical hold on Intellia Therapeutics Inc.‘s (NASDAQ:NTLA) Investigational New Drug application (IND) for the MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).ATTRv-PN is a rare, fatal, autosomal dominant progressive disease where misfolded transthyretin proteins form amyloid deposits in peripheral nerves, causing sensory and motor dysfunction.The compa ...
